Browsing by Author Kantarjian, Hagop

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2010Cause of death in patients with lower-risk myelodysplastic syndromeStevenson, William; Borthakur, Gautam; Conley, Anthony P.; Cortes, Jorge E.; Dayyani, Farshid; Faderl, Stefan; Garcia-Manero, Guillermo; Kantarjian, Hagop; O'Brien, Susan; Pierce, Sherry; Strom, Sara S; Northern Clinical School: MedicineCause of death in patients with lower-risk myelodysplastic syndrome, Cancer, vol.116, 9,pp 2174-2179
2014High Cancer Drug Prices in the United States: Reasons and Proposed SolutionsElshaug, Adam; Kantarjian, Hagop; LIGHT, Donald W.; Sanjuan, Judit; Steensma, David; School of Public Health: Public HealthHigh Cancer Drug Prices in the United States: Reasons and Proposed Solutions, Journal of Oncology Practice, vol.10, 4, 2014,pp e208-e211
2015A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaBasnett, Jordan; Bendall, Linda; Boumber, Yanis; Cortes, Jorge E.; Culotta, Kirk; Daver, Naval; et al, Various; Kantarjian, Hagop; Kawedia, Jitesh; Ravandi, Farhad; Rytting, Michael E; Zeng, Zhihong; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical ResA Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia, Clinical Cancer Research, vol.21, 12, 2015,pp 2704-2714